1. Home
  2. EYPT vs PRTC Comparison

EYPT vs PRTC Comparison

Compare EYPT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • PRTC
  • Stock Information
  • Founded
  • EYPT 1987
  • PRTC 2015
  • Country
  • EYPT United States
  • PRTC United States
  • Employees
  • EYPT N/A
  • PRTC N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • PRTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • EYPT Industrials
  • PRTC Health Care
  • Exchange
  • EYPT Nasdaq
  • PRTC Nasdaq
  • Market Cap
  • EYPT 427.9M
  • PRTC 402.3M
  • IPO Year
  • EYPT 2005
  • PRTC N/A
  • Fundamental
  • Price
  • EYPT $6.51
  • PRTC $17.72
  • Analyst Decision
  • EYPT Strong Buy
  • PRTC Buy
  • Analyst Count
  • EYPT 8
  • PRTC 1
  • Target Price
  • EYPT $25.71
  • PRTC $45.00
  • AVG Volume (30 Days)
  • EYPT 841.5K
  • PRTC 11.3K
  • Earning Date
  • EYPT 05-07-2025
  • PRTC 04-28-2025
  • Dividend Yield
  • EYPT N/A
  • PRTC N/A
  • EPS Growth
  • EYPT N/A
  • PRTC N/A
  • EPS
  • EYPT N/A
  • PRTC N/A
  • Revenue
  • EYPT $43,273,000.00
  • PRTC $468,000.00
  • Revenue This Year
  • EYPT N/A
  • PRTC N/A
  • Revenue Next Year
  • EYPT N/A
  • PRTC $160.00
  • P/E Ratio
  • EYPT N/A
  • PRTC N/A
  • Revenue Growth
  • EYPT N/A
  • PRTC N/A
  • 52 Week Low
  • EYPT $3.91
  • PRTC $13.30
  • 52 Week High
  • EYPT $21.26
  • PRTC $32.98
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 61.19
  • PRTC 53.75
  • Support Level
  • EYPT $5.37
  • PRTC $16.37
  • Resistance Level
  • EYPT $5.86
  • PRTC $16.75
  • Average True Range (ATR)
  • EYPT 0.57
  • PRTC 0.96
  • MACD
  • EYPT 0.20
  • PRTC 0.10
  • Stochastic Oscillator
  • EYPT 99.81
  • PRTC 65.97

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About PRTC PureTech Health plc

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

Share on Social Networks: